Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
66.6M
-
Number of holders
-
82
-
Total 13F shares, excl. options
-
21.1M
-
Shares change
-
-5.41M
-
Total reported value, excl. options
-
$141M
-
Value change
-
-$36M
-
Put/Call ratio
-
1.44
-
Number of buys
-
44
-
Number of sells
-
-40
-
Price
-
$6.66
Significant Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) as of Q3 2021
108 filings reported holding CRDF - Cardiff Oncology, Inc. - Common Stock as of Q3 2021.
Cardiff Oncology, Inc. - Common Stock (CRDF) has 82 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21.1M shares
of 66.6M outstanding shares and own 31.72% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (3.53M shares), CAXTON CORP (2.52M shares), BlackRock Inc. (2.39M shares), VANGUARD GROUP INC (1.81M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.67M shares), Octagon Capital Advisors LP (983K shares), CITADEL ADVISORS LLC (877K shares), Artal Group S.A. (750K shares), TWO SIGMA ADVISERS, LP (701K shares), and STATE STREET CORP (632K shares).
This table shows the top 82 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.